FSHD region gene 2 family member I, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG2IP profile across patient tissues and cancer cell-line models. FRG2IP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, FRG2IP is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, FRG2IP RNA expression shows 6,503 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, LUAD, and STAD as cancer lineages where FRG2IP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2IP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2IP survival associations across molecular data types. FRG2IP RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2IP RNA expression–survival associations across cancer types. High FRG2IP expression shows unfavorable associations in THYM, UCS, STAD, KIRC, COAD and KICH. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify THYM as the clearest survival context for FRG2IP RNA expression.
This table summarizes FRG2IP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2IP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2IP shows higher tumor expression in LUAD and KICH. The LUAD box plot shows higher FRG2IP RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .011).
This table shows molecular features associated with FRG2IP in patient tissues and cancer cell lines. In patient samples, FRG2IP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
